Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tinengotinib in Advanced Cholangiocarcinoma
NCT06057571Phase 2Active, not recruiting
- Sponsor
- TransThera Biosciences
- Start
- Nov 2023
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tinengotinib in cholangiocarcinoma (CCA), sponsored by TransThera Biosciences. Started Nov 2023; status: active, not recruiting.
02
Drugs
tinengotinib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT06057571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06057571.